A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Completed · Phase 1

Conditions studied: Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence

In brief

The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.

Key facts

Study ID

NCT01451632

Run by

Merrimack Pharmaceuticals

People needed

48

Starts

2011-10-01

Expected to finish

2014-06-01

Last updated by the study team

2016-09-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• No standard options remaining
• Adequate liver and kidney functions
• 18 years of age or above

You may not qualify if…

• History of any secondary active cancer in the last 3 years.
• Pregnant or breast feeding
• History of severe allergic reactions or contraindications to cetuximab or irinotecan

Where it is running

• Study site — San Francisco, California, United States
• Study site — Boston, Massachusetts, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.